Orion Pharma wants to produce Russian Covid vaccines

Mostafizur Rahman | Published: 22:11, May 04,2021


Orion Pharma Limited, one of the leading pharmaceutical companies for manufacturing and marketing of general drugs in Bangladesh, has initiated a move to manufacture Covid vaccines in the country.

The company informed the health and family welfare ministry on Tuesday and the Directorate General of Drug Administration on Sunday about its newly developed vaccine manufacturing facility.

In the letters, Orion Pharma said that the company had set up a four-storied building for upcoming pharmaceutical products (none penicillin, none cephalosporin) manufacturing facility.

The facility is under a dedicated HVAC system as well as human and material entry is separate, it said.

The company has communicated with the Russian Direct Investment Fund (RDIF) for the supply of Covid vaccine ‘Sputnik V’ but at this moment, they are supplying vaccine government-to-government.

‘As we have a newly built facility to produce Covid vaccine, we have also approached them for technology transfer, and they have provided us with the detail procedure required for the production of Covid vaccine,’ it said.

‘After analysing the procedure, we have reached a conclusion that we are capable of conforming to any of the stages involved in production cycle of the Covid vaccine,’ it said.

‘As per our communication with the RDIF, initially we have decided to start our production from the fill finish stage and after a certain period of time we can also go for vaccine production from cultivation stage,’ the letter reads.

In order to produce the vaccine, the company is continuously cooperating with the RDIF by proving all the specification as per their requirements, the letter said.

Earlier on April 29, the government decided to manufacture Russian Sputnik V and Chinese Sinophram’s Covid vaccine locally after the supply of Oxford-AstraZeneca vaccine from India under a contract had become uncertain.

Want stories like this in your inbox?

Sign up to exclusive daily email